US2009143725A1PendingUtilityA1

Method of Optimizing Efficacy of Therapeutic Agent

Assignee: ABBOTT DIABETES CARE INCPriority: Aug 31, 2007Filed: Aug 28, 2008Published: Jun 4, 2009
Est. expiryAug 31, 2027(~1.1 yrs left)· nominal 20-yr term from priority
A61B 5/14865A61B 5/14546A61B 5/0002A61B 5/14532
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Method and device for outputting one or more signals associated with a monitored analyte level of an individual, the one or more signals including a substantially real time monitored analyte level and a rate of change information associated with the monitored analyte level, outputting a carbohydrate intake event indication, determining one or more data associated with one or more therapy information related to the monitored analyte level and the meal event indication, and outputting the determined one or more data over the outputted one or more signals associated with the monitored analyte level and the carbohydrate intake event indication are provided.

Claims

exact text as granted — not AI-modified
1 . A therapy management device, comprising:
 a display unit; and   a processor operatively coupled to the display unit, the processor configured to display a carbohydrate intake event indication, and a graphical representation of a monitored substantially real time analyte level and a rate of change information of the monitored analyte level of an individual approaching the meal event indication, the processor further configured to output a therapy related output over the displayed graphical representation of the monitored analyte level of the individual.   
     
     
         2 . The device of  claim 1  wherein the output related to an analyte level of the individual includes a graphical display of a continuous monitored glucose level of the individual. 
     
     
         3 . The device of  claim 1  wherein therapy related output includes one or more of an insulin action curve, an insulin on board information, or a current medication delivery profile information. 
     
     
         4 . The device of  claim 1  further including an insulin delivery unit, wherein the display unit is coupled to the insulin delivery unit. 
     
     
         5 . The device of  claim 1  further including an analyte monitoring unit, wherein the display unit is coupled to the analyte monitoring unit. 
     
     
         6 . A method, comprising:
 outputting one or more signals associated with a monitored analyte level of an individual, the one or more signals including a substantially real time monitored analyte level and a rate of change information associated with the monitored analyte level;   outputting a carbohydrate intake event indication;   determining one or more data associated with one or more therapy information related to the monitored analyte level and the meal event indication; and   outputting the determined one or more data over the outputted one or more signals associated with the monitored analyte level and the carbohydrate intake event indication.   
     
     
         7 . The method of  claim 6 , wherein the output one or more signals includes one or more of a line graph, a bar graph, a 2-dimensional visual display, a three-dimensional visual display, an audible output, a vibratory output, or one or more combinations thereof. 
     
     
         8 . The method of  claim 6  wherein determined one or more data is associated with a medication information for the therapy related to the monitored analyte level. 
     
     
         9 . The method of  claim 6  wherein the carbohydrate intake event indication is associated with a meal event of the individual. 
     
     
         10 . The method of  claim 6  wherein the determined one or more data is output in a superimposed matter over the outputted one or more signals associated with the monitored analyte level and the carbohydrate intake event indication, the determined one or more data including one or more of an insulin action curve, insulin on board information, or a current medication delivery profile information. 
     
     
         11 . The method of  claim 6  wherein the output one or more signals and the determined one or more data are substantially simultaneously displayed on a display unit. 
     
     
         12 . A therapy management device, comprising:
 a communication interface configured to receive one or more data associated with a monitored analyte level, and   a processor coupled to the communication interface, the processor configured to detect a carbohydrate intake event indication, and to detect a predetermined rate of change of the monitored analyte level based on the received one or more data associated with the monitored analyte level, where the processor is further configured to disable one or more therapy related functions executable by a user when the detected predetermined rate of change deviates from a predefined threshold level.   
     
     
         13 . The device of  claim 12  wherein the predetermined rate of change includes a decrease in the analyte level of the user. 
     
     
         14 . The device of  claim 12  wherein the one or more therapy related functions includes one or more medication administration functions. 
     
     
         15 . The device of  claim 12  wherein the processor is configured to temporarily disable the one or more therapy related functions until the detected predetermined rate of change substantially falls within the predefined threshold level. 
     
     
         16 . The device of  claim 12  wherein the predefined threshold level includes a hypoglycemic condition or an impending hypoglycemic condition. 
     
     
         17 . A method, comprising:
 detecting a predetermined rate of change of based on one or more data associated with the monitored analyte level within a predetermined time period of a scheduled meal event; and   modifying an insulin administration profile of an insulin infusion device when the detected predetermined rate of change deviates from a predefined threshold level.   
     
     
         18 . The method of  claim 17  wherein modifying the insulin administration profile includes suspending the infusion of insulin by the insulin infusion device. 
     
     
         19 . The method of  claim 17  wherein modifying the insulin administration profile includes temporarily suspending the infusion of insulin until the detected predetermined rate of change substantially falls within the predefined threshold level. 
     
     
         20 . The method of  claim 17  wherein the predefined threshold level includes a hypoglycemic condition or an impending hypoglycemic condition.

Join the waitlist — get patent alerts

Track US2009143725A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.